Matches in SemOpenAlex for { <https://semopenalex.org/work/W1972625569> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W1972625569 endingPage "69" @default.
- W1972625569 startingPage "64" @default.
- W1972625569 abstract "The treatment of malignant neuroendocrine gut and pancreatic tumors provides a therapeutic challenge. Surgery as well as medical treatment rarely cure the patient at this stage. Symptoms related to secretory products from the tumor might be life-threatening or at least reduce the quality of life considerably. Interferons (IFNs) have demonstrated an antitumor effect in multiple tumor diseases and were introduced by our group in 1982 for the treatment of carcinoids. Today, more than 300 patients with various neuroendocrine tumors and who receive alpha-IFN have been reported in the literature. Treatment of midgut carcinoid tumors at doses of 3-9 MU 3-7 times per week subcutaneously has achieved biochemical responses in 44% of the patients with significant tumor reduction in 11%. Subjective improvement has been obtained in around 65% of the patients. A median survival from start of treatment in patients with carcinoid syndrome of 80+ months has to be compared with 8-12 months on chemotherapy (streptozotocin plus 5-FU). Treatment of endocrine pancreatic tumors with alpha-IFN at doses of 5-6 MU 3-5 times per week achieved biochemical responses in 51% of the patients and tumor responses in 12%. The median duration of response was 20 months (range 2-96). Combining alpha-IFN with the somatostatin analogue octreotide in patients with malignant tumors resistant to octreotide alone got biochemical responses in 77% with 18% complete biochemical remissions. No significant reduction of tumor size was noticed, but stabilization of the disease was obtained for a median of 15 months.(ABSTRACT TRUNCATED AT 250 WORDS)" @default.
- W1972625569 created "2016-06-24" @default.
- W1972625569 creator A5015490909 @default.
- W1972625569 creator A5040645190 @default.
- W1972625569 creator A5047715660 @default.
- W1972625569 date "1994-01-01" @default.
- W1972625569 modified "2023-09-27" @default.
- W1972625569 title "Interf erons Alone or in Combination with Chemotherapy or Other Biologicals in the Treatment of Neuroendocrine Gut and Pancreatic Tumors" @default.
- W1972625569 doi "https://doi.org/10.1159/000201204" @default.
- W1972625569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7698540" @default.
- W1972625569 hasPublicationYear "1994" @default.
- W1972625569 type Work @default.
- W1972625569 sameAs 1972625569 @default.
- W1972625569 citedByCount "49" @default.
- W1972625569 countsByYear W19726255692012 @default.
- W1972625569 countsByYear W19726255692013 @default.
- W1972625569 countsByYear W19726255692016 @default.
- W1972625569 countsByYear W19726255692020 @default.
- W1972625569 crossrefType "journal-article" @default.
- W1972625569 hasAuthorship W1972625569A5015490909 @default.
- W1972625569 hasAuthorship W1972625569A5040645190 @default.
- W1972625569 hasAuthorship W1972625569A5047715660 @default.
- W1972625569 hasConcept C126322002 @default.
- W1972625569 hasConcept C146357865 @default.
- W1972625569 hasConcept C151730666 @default.
- W1972625569 hasConcept C203014093 @default.
- W1972625569 hasConcept C2776178377 @default.
- W1972625569 hasConcept C2776297358 @default.
- W1972625569 hasConcept C2776694085 @default.
- W1972625569 hasConcept C2778108375 @default.
- W1972625569 hasConcept C2778563252 @default.
- W1972625569 hasConcept C2778764654 @default.
- W1972625569 hasConcept C2779066768 @default.
- W1972625569 hasConcept C2781025020 @default.
- W1972625569 hasConcept C2781151469 @default.
- W1972625569 hasConcept C2909179924 @default.
- W1972625569 hasConcept C46699223 @default.
- W1972625569 hasConcept C71315377 @default.
- W1972625569 hasConcept C71924100 @default.
- W1972625569 hasConcept C86803240 @default.
- W1972625569 hasConcept C90924648 @default.
- W1972625569 hasConceptScore W1972625569C126322002 @default.
- W1972625569 hasConceptScore W1972625569C146357865 @default.
- W1972625569 hasConceptScore W1972625569C151730666 @default.
- W1972625569 hasConceptScore W1972625569C203014093 @default.
- W1972625569 hasConceptScore W1972625569C2776178377 @default.
- W1972625569 hasConceptScore W1972625569C2776297358 @default.
- W1972625569 hasConceptScore W1972625569C2776694085 @default.
- W1972625569 hasConceptScore W1972625569C2778108375 @default.
- W1972625569 hasConceptScore W1972625569C2778563252 @default.
- W1972625569 hasConceptScore W1972625569C2778764654 @default.
- W1972625569 hasConceptScore W1972625569C2779066768 @default.
- W1972625569 hasConceptScore W1972625569C2781025020 @default.
- W1972625569 hasConceptScore W1972625569C2781151469 @default.
- W1972625569 hasConceptScore W1972625569C2909179924 @default.
- W1972625569 hasConceptScore W1972625569C46699223 @default.
- W1972625569 hasConceptScore W1972625569C71315377 @default.
- W1972625569 hasConceptScore W1972625569C71924100 @default.
- W1972625569 hasConceptScore W1972625569C86803240 @default.
- W1972625569 hasConceptScore W1972625569C90924648 @default.
- W1972625569 hasIssue "3" @default.
- W1972625569 hasLocation W19726255691 @default.
- W1972625569 hasLocation W19726255692 @default.
- W1972625569 hasOpenAccess W1972625569 @default.
- W1972625569 hasPrimaryLocation W19726255691 @default.
- W1972625569 hasRelatedWork W1964914447 @default.
- W1972625569 hasRelatedWork W1972625569 @default.
- W1972625569 hasRelatedWork W2067145018 @default.
- W1972625569 hasRelatedWork W2131492952 @default.
- W1972625569 hasRelatedWork W2170467390 @default.
- W1972625569 hasRelatedWork W2398048903 @default.
- W1972625569 hasRelatedWork W2402882835 @default.
- W1972625569 hasRelatedWork W2411766209 @default.
- W1972625569 hasRelatedWork W2418417937 @default.
- W1972625569 hasRelatedWork W635341612 @default.
- W1972625569 hasVolume "55" @default.
- W1972625569 isParatext "false" @default.
- W1972625569 isRetracted "false" @default.
- W1972625569 magId "1972625569" @default.
- W1972625569 workType "article" @default.